Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells

Cellular Physiology and Biochemistry

Volumn 9, Issue 3, 1999, Pages 117-125

  Wagenknecht, Bettina ^a   Hermisson, Mirjam ^a   Eitel, Katrin ^a   Weller, Michael ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Glioma; p21; p53; Proteasome

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BROPARESTROL; CALPASTATIN; LACTACYSTIN; LEUPEPTIN; LN 308; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPSTATIN; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P53; TOSYLLYSYL CHLOROMETHYL KETONE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; COLON CARCINOMA; ENZYME ACTIVATION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INDUCTION;

EID: 0032841656     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016308     Document Type: Article

References (19)

1. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53: 3976-3985.
2. Kaufmann SH: Proteolytic cleavage during chemotherapy-induced apoptosis. Mol Med Today 1996;2: 298-303.
3. Cohen GM: Caspases: The executioners of apoptosis. Biochem J 1997;326:1-16.
4. Maeda S, Lin KH, Inagaki H, Saito T: Induction of apoptosis in primary culture of rat hepatocytes by protease inhibitors. Biochem Mol Biol Int 1996;39:447-453.
5. Zhu W, Murtha PE, Young CY: Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. Biochem Biophys Res Commun 1995;214:1130-1137.
6. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: Inhibitors of the proteasome block the degradation of mots cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-771.
7. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, Kawashima S: Apoptosis induction resulting from proteasome inhibition. Biochem J 1996;317:385-388.
8. Lopes UG, Erhardt P, Yao R, Cooper GM: p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997;272:12893-12896.
9. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells: Induction and modulation of sensitivity by cytokines. J Clin Invest 1994;94:954-964.
10. Rieger J, Ständer M, Löschmann PA, Heneka M, Dichgans J, Klockgether T, Weller M: Synthesis and biological effect of NO in malignant glioma cells: Modulation by cytokines including CD95L and TGF-, dexamethasone, and p53 gene transfer. Oncogene 1998;17:2323-2332.
11. Wagenknecht B, Schulz JB, Gulbins E, Weller M: Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Cell Death Differ 1998;5:894-900.
12. Magae J, Illenye S, Tejima T, Chang YC, Mitsui Y, Tanaka K, Omura S, Heintz NH: Transcriptional squelching by ectopic expression of E2F-1 and p53 is alleviated by proteasome inhibitors MG-132 and lactacystin. Oncogene 1997;15:759-769.
13. Maki CG, Huibregtse JM, Howley PM: In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 1996;56:2649-2654.
14. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994;54:649-652.
15. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, Von Deimling A, Dichgans J: Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. Int J Cancer 1998;18:640-644.
16. Blagosklonny MV, Wu GS, Omura S, El-Deiry WS: Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 1996;227:564-569.
17. Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J, Groscurth P: Topoisomerase-I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int J Cancer 1997;73:707-714.
18. Naumann U, Durka S, Weller M: Dexamethasone-mediated protection from drug toxicity linked to p21 protein accumulation. Oncogene 1998;17:1567-1576.
19. Drexler HC: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997;94:855-860.